The reduction in price target by Canaccord Genuity could have a mixed impact on Inari Medical's stock. While maintaining a Buy rating indicates a positive outlook on the company, the lowered price target may reflect concerns about future growth prospects or market conditions that could temper investor enthusiasm in the short term.